Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinion.
Caputo R, Buono G, Di Lauro V, Cianniello D, Von Arx C, Pensabene M, Pagliuca M, Pacilio C, Di Rella F, Verrazzo A, Martinelli C, Nuzzo F, De Laurentiis M.
Caputo R, et al. Among authors: pensabene m.
Future Oncol. 2023 Aug;19(24):1695-1708. doi: 10.2217/fon-2023-0361. Epub 2023 Aug 22.
Future Oncol. 2023.
PMID: 37605877
Review.